

Table 2. Main studies of BRAF inhibitors in metastatic CRC.

Regimen (Author, reference)	RR, %	mPFS, mo
Single/Doublet BRAF/MEK		
Vemurafenib (Kopetz S. JCO 2015)	5	2.1
Dabrafenib (Falchook GS. Lancet 2012)	11	NR
Encorafenib (Gomez-Roca C. ESMO 2014)	6	4
Dabrafenib + Trametinib (Concoran R. JCO 2015)	12	3.5
Doublet with EGFR		
Vemurafenib + Panitumumab (Yaeger R. Clin Ca R 2015)	13	3.2
Vemurafenib + Cetuximab (Tabernero J. ASCO 2014)	20	3.2
Encorafenib + Cetuximab (van Geel R. Canc Disc 2017)	19	3.7
Dabrafenib + Panitumumab (Atreya CE, ASCO 2015)	10	3.4
Triplet with EGFR		
Vemurafenib + Cetuximab + Irinotecan (Hong D. Cancer Discov 2017)	35	7.7
Dabrafenib + Trametinib + Panitumumab (Atreya CE, ASCO 2015)	26	4.1
Encorafenib + Cetuximab + Alpelisib (van Geel R. Cancer Discov 2017)	18	4.2
Encorafenib + Cetuximab +/- Binimetinib vs Cetuximab + Irinotecan or FOLFIRI (Kopetz S. NEJM 2019)	26.8 / 19.5 vs 1.9	4.5 / 4.3 vs 1.5 [mOS: 9.3/9.3 vs 5.9]
Encorafenib + Cetuximab + Binimetinib (1 st line) (Van Cutsem E. ESMO 2021)	47.5	5.8